Open Nav

Chameleon Biosciences

  • Genine Winslow, Chameleon Biosciences (UCSF)


  • Date:Thursday, October 18
  • Time:9:30 AM - 9:45 AM
  • Room:Elizabethan A
  • Location:2nd Floor
  • Session Type:Company Presentation
  • Presentation Type:Privately Funded Company
  • Company Description/Mission Statement:Chameleon Biosciences is a next generation gene therapy company. We are building on current Adeno Associated Virus (AAV) virus technology to make our products invisible to a patient’s immune system and resistant to pre-existing antibodies. Reduced immunogenicity enables repeat dosing which doubles the number of severe Hemophilia patients that we can treat as compared to current technologies, increasing the accessible market by ~9B (US and EU). Chameleon technology changes the current single dose paradigm by using AAV based gene therapies for precise dosing with repeated gene delivery as needed to maintain clinical efficacy in dividing and non-dividing cell types. Chameleon is focusing initially on treating rare orphan diseases beginning with Severe Hemophilia and Niemann Pick Type C. Our platform technology can be applied to all current gene therapy markets, new markets in rare diseases, and non-orphan disease markets.
  • Company Website:
  • Company HQ City:San Anselmo
  • Company HQ Country:United States
  • Company HQ State:California                  
  • CEO/Top Company Official:Genine Winslow
  • Year Founded:2017
  • Main Therapeutic Focus:Gene/Cell Therapy
  • Lead Product in Development :Hemophilia A
  • Development Phase of Primary Product:Discovery
  • Number Of Unlicensed Products (For Which You Are Seeking Partners) :2
  • Additional Information/Comments:Will be raising a $21M series A, starting with a $750K convertible note.
  • Previous and Current Investors:Private Qualified Angel, Berkeley SkyDeck Fund
  • Size of Last Investment Round:$100,000
  • Total Amount Raised to Date, In All Rounds:$170,000
Genine Winslow
Chameleon Biosciences (UCSF)